Correspondence 0001213900-22-082177 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: Dec. 22, 2022 · CIK: 0001601936 · Accession: 0001213900-22-082177
AI Filing Summary & Sentiment
File numbers found in text: 333-268838
Letter
Re: Altamira Therapeutics Ltd. (the “Company”)
December 22, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-1 (File No. 333-268838)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:05 p.m. Eastern Time on December 27, 2022, or as soon thereafter as is practicable.
Please call Alan Wovsaniker of Lowenstein Sandler LLP at 973-597-2564 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
Altamira Therapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
December 22, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Altamira Therapeutics Ltd. (the “Company”)
Registration Statement on Form F-1 (File No. 333-268838)
Ladies and Gentlemen:
In accordance with Rule 461 under
the Securities Act of 1933, as amended, the Company hereby requests that the effective date for the Registration Statement referred to
above be accelerated so that it will be declared effective at 4:05 p.m. Eastern Time on December 27, 2022, or as soon thereafter as is
practicable.
Please call Alan Wovsaniker of
Lowenstein Sandler LLP at 973-597-2564 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
Altamira Therapeutics Ltd.
By:
/s/ Thomas Meyer
Name:
Thomas Meyer
Title:
Chief Executive Officer